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Abstract
The available evidence suggests that protective immunity to Leishmania is achieved by priming the CD4+ Th1 response.
Therefore, we utilised a reverse genetics strategy to generate influenza A viruses to deliver an immunogenic Leishmania
peptide. The single, immunodominant Leishmania-specific LACK158–173 CD4
+ peptide was engineered into the
neuraminidase stalk of H1N1 and H3N2 influenza A viruses. These recombinant viruses were used to vaccinate susceptible
BALB/c mice to determine whether the resultant LACK158–173-specific CD4
+ T cell responses protected against live L. major
infection. We show that vaccination with influenza-LACK158–173 triggers LACK158–173-specific Th1-biased CD4
+ T cell
responses within an appropriate cytokine milieu (IFN-c, IL-12), essential for the magnitude and quality of the Th1 response.
A single intraperitoneal exposure (non-replicative route of immunisation) to recombinant influenza delivers immunogenic
peptides, leading to a marked reduction (2–4 log) in parasite burden, albeit without reduction in lesion size. This correlated
with increased numbers of IFN-c-producing CD4+ T cells in vaccinated mice compared to controls. Importantly, the
subsequent prime-boost approach with a serologically distinct strain of influenza (H1N1-.H3N2) expressing LACK158–173 led
to a marked reduction in both lesion size and parasite burdens in vaccination trials. This protection correlated with high
levels of IFN-c producing cells in the spleen, which were maintained for 6 weeks post-challenge indicating the longevity of
this protective effector response. Thus, these experiments show that Leishmania-derived peptides delivered in the context
of recombinant influenza viruses are immunogenic in vivo, and warrant investigation of similar vaccine strategies to
generate parasite-specific immunity.
Citation: Kedzierska K, Curtis JM, Valkenburg SA, Hatton LA, Kiu H, et al. (2012) Induction of Protective CD4+ T Cell-Mediated Immunity by a Leishmania Peptide
Delivered in Recombinant Influenza Viruses. PLoS ONE 7(3): e33161. doi:10.1371/journal.pone.0033161
Editor: Mauricio Martins Rodrigues, Federal University of Sa˜o Paulo, Brazil
Received October 25, 2011; Accepted February 5, 2012; Published March 21, 2012
Copyright:  2012 Kedzierska et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Australian National Health and Medical Research Council, (Project Grant 406631 and Program Grant 406601), NHMRC
Independent Research Institutes Infrastructure Support Scheme grant #361646, and Victorian State Government Operational Infrastructure Support grant. KK is
an NHMRC RD Wright Research Fellow. LAH and HK are recipients of an NHMRC Biomedical Postgraduate Research Scholarship, and SAV is a recipient of the
Australian Postgraduate Scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: kkedz@unimelb.edu.au (KK); kedzierski@wehi.edu.au (LK)
Introduction
Leishmania protozoan parasites shuttle between the sand fly
vector, where they multiply as free promastigotes in the gut lumen,
and mammalian hosts where they proliferate as obligatory
intracellular amastigotes in mononuclear phagocytes [1]. Leish-
maniases constitute a family of conditions, with discrete clinical
features ranging from cutaneous lesions to a fatal systemic disease.
Prevalent in Africa, Latin America, Asia, the Mediterranean basin
and the Middle East, leishmaniasis has even been identified in
Australia in kangaroos [2]. One of the great neglected diseases, the
estimated disease burden places Leishmania second in mortality and
fourth in morbidity among the tropical infections [3]. Sharp rises
in distribution and prevalence have been related to environmental
changes and to the migration of non-immune people to endemic
areas [4]. The former, in particular, has the potential to expand
the geographic span of the vector, thus increasing Leishmania
transmission to previously unaffected areas [5].
Current treatment is based on chemotherapy, relying on a
handful of drugs with serious limitations such as high cost and
toxicity, difficult route of administration and lack of efficacy in
some endemic areas [6]. Development of a successful vaccine has
been a goal for almost a century. There are many barriers to
developing an antileishmanial vaccine, but a major issue has been
that the traditional approaches have worked poorly. The first
generation, whole-cell killed vaccines have been inadequately
defined and variable in potency, leading to inconclusive results in
field trials. In general, reproducible evidence of protective efficacy
has not emerged from clinical trials of first generation leishman-
iasis vaccines. The focus is now on the second generation vaccines
including genetically modified parasites and defined subunit
vaccines, however to date, their efficacy in the field trials has not
been reported. Virally vectored vaccines emerged as novel
platforms that might address the deficiencies of traditional delivery
systems, particularly where cell mediated responses are needed for
protection. Influenza viruses are attractive candidates as vaccine
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vectors, with the approach being tried so far for HIV [7],
tuberculosis [8], malaria [9] and cancer [10]. These results point
to the value of recombinant influenza vectors for Leishmania
vaccination. Influenza viruses can be easily manipulated by a
reverse genetics strategy [11], which repositions existing immu-
nogenic peptides [12] or inserts additional epitopes into influenza
segments [13,14] to elicit prominent CD8+ T cell responses.
‘‘Cold-adapted’’ influenza has been approved for human use
(FluMist) [15], and the capacity to readily manipulate the
immunogenic peptide in the context of influenza vector makes it
easy to apply the vaccine to a number of antigenic candidates. In
the present study, we utilised a model of recombinant influenza
expressing a single, Leishmania-specific LACK158–173 (Leishmania
homologue of receptors for activated C kinase) CD4+ T cell
peptide. This sequence has been identified by peptide mapping as
the major LACK component presented by the I-Ad MHC
molecule [16]. LACK also has the advantage of being a conserved
antigen expressed not only in the sand fly promastigote stage, but
importantly, in disease-causing mammalian amastigotes [17], and
has been shown to react with sera from patients with cutaneous
and visceral leishmaniasis [18]. Here we show that LACK158–173
influenza prime/boost immunisation resulted in considerable
protection against Leishmania in a stringent mouse model of
disease, and was associated with increased IFN-c production by
LACK158–173-specific CD4
+ T cells in vaccinated animals.
Methods
Mice, viral immunisations and parasite infections
Ethics Statement: Mice were bred at the Walter and Eliza Hall
Institute’s animal facility. Animal experiments followed the
NHMRC Code of Practice for the Care and Use of Animals for
Scientific Purposes guidelines and have been approved by the
Walter and Eliza Hall Institute’s Animal Ethics Committee (AEC
Projects 2005.012 and 2008.003).
L. major virulent clone V121 was derived from the L. major isolate
LRC-L137 [19] and maintained at 26uC in M199 medium
supplemented with 10% (v/v) heat inactivated FBS (Trace
Biosciences, NSW, Australia).
The 8 weeks (wk) old naı¨ve BALB/c mice were vaccinated i.p.
with 1.56107 pfu of recombinant influenza A virus in PBS. Mice
primed with the PR8-LACKins virus received a booster injection at
4 wk following priming. PR8 virus controls or PBS controls were
included in each experiment. Mice were challenged by intrader-
mal injection of 106 virulent L. major live promastigotes at the base
of the tail 2 or 6 wk following priming or boosting. Virulent
parasites were obtained from a Balb/c mouse infected lesion,
which was placed into biphasic blood agar (NNN) medium.
Parasites were then passaged in NNN with M119 overlay and left
for 6 days when they reached the stationary phase.
Lesion development was monitored using a semi-quantitative
scoring of lesion diameter [20]. The following scoring was
employed: 0 = no lesion or minor injection or healing scar;
1 = small swelling or lesion approximately 1mm in diameter; 2
= large swelling or lesion 1–5mm in diameter; 3 = lesion 5–
10mm in diameter; 4 = lesion greater than 10mm in diameter
and/or metastasis. Data are expressed as the arithmetic mean 6
standard error of the lesion score for the group of mice.
Generation and titration of recombinant viruses
Recombinant viruses were produced by an 8-plasmid reverse
genetics system [11]. The LACK158–173 sequence was introduced
into the neuraminidase (NA) segment of the H1N1 A/PR8/34
(PR8) virus at position p 42 using either a replacement (LACKrep)
or insertion strategy (LACKins), and into the H3N2 A/HKx31
(X31) virus at position p 45 using the insertion strategy. The
LACK158–173 constructs were amplified by PCR from PR8 or X31
genomic template using primers NA-L PR8insF (TTCTCGC-
CGTCGCTGGAGCATCCGATCGTGGTGTCCGGCAGCT-
GGGACCAAAACCATACTGGAATATGCAACCAAAACAT-
C) and NA-L PR8insR (GTCCCAGCTGCCGGACACCACG-
ATCGGATGCTCCAGCGACGGCGAGAAACTTCCAGTTT-
GAATTGAATGGCTAATCC) for PR8-LACKins; NA-L PR8repF
(TTCTCGCCGTCGCTGGAGCATCCGATCGTGGTGTCC-
GGCAGCTGGGACCAAAACATCATTACCTATAAAAATA-
GCACC) and NA-L PR8repR (as NA-L PR8insR) for PR8-
LACKrep; NA-L x31p45F (TTCTCGCCGTCGCTGGAGCA-
TCCGATCGTGGTGTCCGGCAGCTGGGACCCCGCGAG-
CAACCAAGTAATGCCGTGTGAA) and NA-L x31p45R (GTC-
CCAGCTGCCGGACACCACGATCGGATGCTCCAGCGAC-
GGCGAGAAGGAGTC GCACTCATATTGCTTAAAATGCA-
ATG) for X31-LACK. The regions flanking the LACK epitope
within the NA segment are shown in Table S1.
PCR products were digested with BsmB1 or BsaI and ligated
into pHW2000 vector. The recombinant viruses containing
LACK158–173 (PR8-LACKins, PR8-LACKrep and X31-LACK)
were rescued after transfection of 8 plasmids encoding influenza
segments into 293T and MDCK cells. Viruses were amplified in
the allantoic cavity of d10 embryonated hen’s eggs and quantified
as plaque-forming units (pfu) on monolayers of MDCK cells. The
infectious titres of the viruses were 2.66108, 4.66108, 2.26108,
8.46108 and 7.746108 pfu/ml for PR8, PR8-LACKins, PR8-
LACKrep, X31 and X31-LACK, respectively. We ensured that the
viral NA construct expressed LACK158–173 insert by firstly
sequencing the NA plasmid prior to the reverse genetics rescue
of the virus, then by sequencing the amplified virus within the
allantoic fluid directly from the egg, prior to infection the mice
with engineered virus.
Tissue sampling and cell preparation
Spleens and draining lymph nodes (dLN) were recovered from
mice at day 10 following immunisation and at different time-points
after Leishmania infection (as indicated in the Results). Inguinal
dLN were removed after Leishmania infection. Spleens and dLN
were passed through 40 mm sieves to generate single cell
suspension. Parasite burdens were determined by limited dilution
analysis [21].
Cytokine analyses
Cytokine levels were assessed by capture ELISA and Intracel-
lular Cytokine Staining (ICS) [22]. Briefly, for in vitro stimulation
splenic and dLN cells were resuspended in C-RPMI medium
supplemented with 10% FBS, 2-mercaptoethanol, antibiotics and
L-glutamine, plated in 48-well plates (Costar, NY, USA) in the
presence of 46106 irradiated (3000 rad) splenocytes and stimulat-
ed for 3 days at 37OC with LACK158–173 peptide or SLA. For ex
vivo stimulation with the LACK158–173 peptide no additional APCs
were used, cells were stimulated for 12 h (8 h in the presence of
brefeldin A). For ELISA, culture supernatants were collected
following LACK158–173 or SLA stimulation. U-bottom 96-well
plates (Thermo Labsystems, MA, USA) coated with capture
antibodies against IL-4, IL-10, IL-12(p 40/p 70) and IFN-c (BD
Pharmingen, CA, USA) were incubated overnight at 4OC with
serial dilutions of culture supernatants in duplicates, washed and
incubated for 2 h at RT with biotin anti-mouse IL-4, IL-10, IL-
12(p 40/p 70) and IFN-c, followed by incubation with streptavi-
din-horseradish peroxidase (1:5000). Plates were developed with
ABTS in 0.1 M citric acid pH 4.2. Absorbance values were read
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at 405 nm. Bio-Plex Pro Mouse Cytokine 23-plex assay was
performed according to the manufacturers’ instructions (BioRad
Laboratories Inc., CA, USA). For ICS, cultured cells were re-
stimulated with 50 ng/ml PMA and 500 ng/ml ionomycin in the
presence of 2 mg/ml brefeldin A for 4 h at 37OC. Cells were
stained for surface markers CD4-PE, CD8-PerCP and CD44-APC
or FITC, fixed and permeabilised. Cells were stained for either
IFN-c-FITC or IL-4-APC (BD Pharmingen, CA, USA). Cell
fluorescence was measured by flow cytometry using a FACSCa-
libur flow cytometer and data were analysed using BD CellQuest
Pro software. LACK158–173 peptide was purchased from Auspep
(Australia).
Statistical analyses
Statistical analyses were performed using unpaired t-test [23,24]
provided within GraphPad Prism 5 software and Compare
Groups of Growth Curves software package available on the
Bioinformatics Division’s website http://bioinf.wehi.edu.au/.
Results
Priming with recombinant influenza viruses skews the
response to Th1-type
Recombinant PR8 (H1N1) viruses expressing LACK158–173
were used to prime susceptible BALB/c mice for the initial
characterisation of LACK-specific Th1 and Th2 CD4+ T cell
responses in comparison to naı¨ve controls. Intraperitoneal priming
of mice with influenza does not lead to a productive viral
replication, but allows a one-stop growth cycle with full protein
production that results in priming of antigen-specific effector T
cells in the spleen and the establishment of long-term T cell
memory. Although the viruses are replication-competent, they
cannot produce infectious progeny due to the absence of the
trypsin-like enzyme, which in the wild-type virus cleaves the viral
haemagglutinin (HA) in the respiratory tract [25,26].
Two viral constructs expressing the LACK158–173 peptide were
initially tested for the ability to generate anti-leishmanial
responses. Mice were immunised i.p with virus expressing either
the LACK peptide sequence inserted within the influenza
neuraminidase (NA) gene (LACKins), or with virus in which the
LACK sequence replaces a segment of the gene (LACKrep) (Table
S1). Cells were obtained from spleens at the peak of T cell
responses (day 10 (d 10) post-priming) and analysed by a number
of assays, including ICS for IFN-c and IL-4 (Th1 vs Th2), and
ELISA to determine the presence of IFN-c and IL-12 (Th1) versus
IL-4 and IL-10 (Th2) in the culture supernatants. Our data show
that priming with influenza-LACK158–173 elicits LACK-specific
CD4+ T cells on d 10, suggesting that a single i.p. immunisation
can efficiently deliver immunogenic peptides in the context of a
recombinant virus. Following 12 h ex vivo stimulation with the
LACK158–173 peptide, a distinct LACK158–173
+CD4+ T cell
population in the spleens of vaccinated mice produced IFN-c
(Fig. 1A), but no IL-4 (data not shown), indicating that LACK158–
173 vaccination in the context of influenza induces a Th1-bias.
Similar results were obtained after either 24 or 72 h in vitro culture
with the LACK158–173 peptide, when cells were tested for IFN-c
production by ICS assay (Fig. 1B) and by ELISPOT (data not
shown). Assessment of multiple cytokine production in the culture
supernatant further showed that priming with influenza-
LACK158–173 induced Th1 responses as the LACK158–173
stimulated T cells produced IFN-c and IL-12, but not IL-4 or
IL-10 (very low levels of IL-10 were detected following PR8-
LACKins most likely due to influenza itself, which has been shown
to induce IL-10 [27]) (Fig. 2). Interestingly, PR8-LACKins
appeared to be more efficient in the induction of specific CD4+
T cells than PR8-LACKrep (Figs. 1, 2), suggesting that the
molecular context influences epitope processing and presentation.
Accordingly, PR8-LACKins was used in further experiments.
Priming with PR8-LACKins or PR8-LACKrep did not induce
significant IFN-c production by CD4-negative lymphocytes, which
was comparable to the naı¨ve controls (P.0.05) (data not shown).
Hence, our results establish that vaccination with LACK158–173
peptide in the context of influenza virus delivered by a non-
replicative route of immunisation induces antileishmanial
LACK158–173-specific CD4
+ T cells polarised towards protective
Th1 responses and prompted us to evaluate the protective capacity
of these responses.
Protective efficacy of LACK+CD4+ T cells in influenza-
LACK primed susceptible BALB/c mice
In order to assess protective efficacy of LACK158–173-specific
CD4+ T cells generated after a single i.p. immunisation with
influenza-LACK158–173 viruses against Leishmania challenge, we
performed immunisation trials in Balb/c mice. Animals were
primed with recombinant influenza-LACK158–173 viruses and
were challenged with 106 L. major promastigotes at the base of the
tail. To monitor the progress of infection, spleens and draining
(d)LN were harvested and assessed for parasite burden and
cytokine production, and lesion development was monitored
weekly. LACK158–173-primed susceptible BALB/c mice were
partially protected against Leishmania infection and showed
reduced lesion scores (Fig. 3A) and significantly lower parasite
burdens (2–4 log reduction at 11 wk) (Fig. 3B) compared to wild-
type (WT) PR 8 virus-primed controls. Even so, while priming led
to a substantial decrease in parasite burden, differences in lesion
scores did not reach statistical significance. Protection correlated
with increased number of IFN-c producing cells in the spleen of
PR8-LACKins vaccinated mice (and also PR8-LACKrep, but to a
lesser extent; data not shown) in comparison with the WT PR8
(vector only) primed controls (Fig. 3C). Thus, it seems that
LACK158–173-specific CD4
+ T cells generated following immuni-
sation do confer some protection in mice primed with a single dose
of replicative influenza-LACK virus delivered bv intraperitoneal
route.
Prime-boost strategy enhances protection and
persistence of CD4+ T cell responses
LACK158–173-specific CD4
+ T cells primed by viruses delivered
by a non-replicative route of immunisation can provide partial
protection against subsequent live parasitic challenge. However,
natural infection provides a low level of sustained antigenic
stimulation due to parasite persistence, which puts a considerable
constraint on vaccine efficacy. Therefore, boosting might be
necessary to ensure prolonged protection requiring Th1 responses
and induction of high frequencies of specific CD4+ T cells. The
influenza vector can be easily manipulated by reverse genetics to
avoid any pre-existing humoral immunity and allow periodical
boosting, an advantage over other virus-based vaccines (eg.
vaccinia). To test the suitability of our system for the prime-boost
regimen, mice were primed with PR8-LACKins virus and boosted
4 wk later with X31-LACKins recombinant influenza. They were
then challenged 2 wk following boosting with the parasites and
infection was followed for 11 wk. The results showed that
immunised mice had significantly (p,0.0001) reduced lesion size
(Fig. 4B) as well as reduced parasite burdens (p = 0.009) at the end
of the trial compared to PBS controls (Fig. 4C). Protection
correlated with a significantly increased number of IFN-c
Recombinant Influenza as Antileishmanial Vaccine
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producing cells in the spleen of vaccinated mice compared to
controls, but unlike the situation following priming only, this
elevated effector response was still maintained at 6 wk post-
challenge indicating that the duration of the protective response
has been significantly extended following boosting (Fig. 4D).
Moreover, there was a significant expansion of peptide specific
CD4+ IFN-c producing cells at the site of infection (dLN).
Significantly higher cell numbers were detected in immunised and
challenged mice at wk 2 (p = 0.02) and wk 6 (p = 0.002) compared
to pre-challenge levels in unimmunised mice. The expansion of
LACK-specific CD4+ T cells increased from wk 2 to wk 6
(p = 0.03) and was also significantly higher in immunised mice at
wk 2 (p = 0.005) when compared to non-immunised controls.
Although at wk 6 the difference in CD4+ IFN-c producing cells
between control and immunised animals was not significantly
different, it is worth pointing out that there was only one (out of 3)
Figure 1. Cytokine production by LACK158–173-specific CD4
+ T cells following influenza-LACK158–173 priming. A) Ex vivo IFN-c
production by LACK158–173-specific CD4
+ T cells. Cells were obtained from spleens of naı¨ve control mice or PR8-LACKins and PR8-LACKrep mice on day
10 following priming. Cells were cultured in the absence or presence of LACK158–173 peptide for 12 h and assessed for IFN-c production by ICS. B) In
vitro IFN-c production by LACK158–173-specific CD4
+ T cells. Cells were obtained from spleens of naı¨ve control mice or PR8-LACKins and PR8-LACKrep
mice on day 10 following priming. Cells were cultured in the absence or presence of LACK158–173 peptide for 72 h followed by re-stimulation with
PMA and ionomycin, and assessed for IFN-c production by ICS. Numbers in the upper right quadrant refer to percentage of CD4+ T cells producing
IFN-c (raw data). Cells have been gated on CD4+ CD44+, for statistical analyses no peptide (panel A) and isotype control (panel B) values were
subtracted from the raw values. Representative data from one mouse are shown (n = 3, n refers to number of mice, *p = 0.004, **p = 0.0002,
***p = 0.006).
doi:10.1371/journal.pone.0033161.g001
Figure 2. Cytokine profile of LACK158–175 specific CD4
+ T cells. Cells were obtained from spleens of naı¨ve control mice or PR8-LACKins and
PR8-LACKrep mice on day 10 following priming. Cells were cultured in the presence of LACK158–173 peptide for 72 h, and culture supernatants were
analysed for cytokine production by capture ELISA. Mean, pooled data 6 SD are plotted (n = 3, n refers to number of mice) *p = 0.001, **p = 0.003,
***p = 0.009, ****p = 0.01, ND – below detection level.
doi:10.1371/journal.pone.0033161.g002
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control mouse that showed specific responses, whereas relatively
high numbers of CD4+ IFN-c producing T cells were detected in
all immunised mice tested in the assay. No IL-4 production was
detected in either the spleen or dLN (data not shown).
Prime-boost regimen increases longevity of the LACK158–
173-specific CD4
+ T cell response
Subsequently, we tested whether our system could be used to
trigger long-term protection. Mice were primed with PR8-
LACKins virus (or PR 8 vector alone) and boosted 4 wk later
with X31-LACKins recombinant influenza (or X31 vector alone).
Animals were then challenged 6 wk following boosting and
infection was followed for 10 wk. Data showed that immunised
mice had significantly (p = 0.0001) reduced lesion size (Fig. 5B) as
well as reduced parasite burdens (p = 0.049) at the end of the trial
(Fig. 5C). Similarly to the short-term prime-boost experiment,
protection correlated with an increased number of LACK158–173-
specific CD4+ IFN-c producing cells in the spleen of vaccinated
mice, with the elevated effector response being maintained at 6 wk
post-challenge (Fig. 5D). These levels were significantly higher pre-
challenge, at wk 2 and 6 (p = 0.02, p = 0.02 and p = 0.01,
respectively) in immunised mice compared to controls. There
was also a marked increase in numbers of CD4+ IFN-c producing
cells in the spleen of vaccinated mice at wk 2 compared to the pre-
challenge levels, but this did not reach a level of statistical
significance. The CD4+ IFN-c producing profiles in the spleen
were similar to those observed previously, but unlike in the
previous experiment (Fig. 4D), we did not see an expansion of
Figure 3. Protective efficacy of influenza-LACK158–173 vaccination. A) Lesion scores in mice vaccinated with LACKins and PR 8 vector controls
(pooled data from 2 independent experiments). B) Parasite burdens in mice vaccinated with LACKins (n = 5), PR 8 vector control (n = 5), *p = 0.02. C)
Cytokine production following challenge infection. Spleens and dNL from vaccinated and control mice were assessed by ex vivo ICS IFN-c (*p = 0.006).
Mean, pooled data from 2 independent experiments 6 SEM are plotted (n = 6 for wk 2, n = 5 for wk 6, n refers to number of mice). Cells have been
gated on CD4+ CD44+.
doi:10.1371/journal.pone.0033161.g003
Figure 4. Boosting with serologically distinct recombinant virus increases protective potency of the effector response. A) Prime-
boost and challenge strategy. B) Lesion scores in mice primed with PR8-LACKins and boosted with X31-LACKins (PR8/X31); and PBS controls. C)
Parasite burdens in PR8/X31 vaccinated mice and PBS controls (n = 3 for wk 2 and 6, n = 5 for wk 11), *p = 0.009. D) Cytokine production following
challenge. Spleens and dNL from vaccinated and control mice were assessed by ex vivo ICS for IFN-c production. Mean, pooled data 6 SEM are
plotted (n = 3 for non-challenged mice, n = 5 for wk 2 and 6); *p = 0.02, **p = 0.03, ***p= 0.005, ****p = 0.001, #p= 0.02, ##p = 0.002, ###p = 0.03.
Cells have been gated on CD4+ CD44+.
doi:10.1371/journal.pone.0033161.g004
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peptide specific CD4+ IFN-c producing T cells in dLN of
vaccinated animals. In addition, we analysed the cytokine profile
of the long-term prime-boost and control mice (multiplex analysis
of 23 different cytokines and chemokines) in the spleen and dLN at
wk 2 and 6 post-challenge, following 3 day in vitro stimulation with
SLA. Although, the differences did not reach the level of statistical
significance, our data show that at wk 2 in the spleen of
immunised mice there was a higher level of IFN-c (Fig. 6).
Conversely, the control mice primed with PR 8 and boosted with
X31 vectors, displayed higher levels of Th2-type cytokines (IL-4,
IL-5, IL-10 and IL-13) in the dLN at wk 2 post-challenge (Fig. 6).
At wk 6 post-challenge there was no difference in cytokine
production between control and immunised mice (data not
shown), indicating that the cytokines may play a crucial role early
during the infection. No difference was also observed in the spleens
at different time points or in the Th1 (IFN-c, Il-2, TNF-a and IL-
3) cytokine profile (data not shown).
Although we found only trends towards increased Th1 IFN-c
production and trends towards decreased Th2 IL-4, IL-5, IL-10 and
IL-13 cytokine production (Fig. 6) in immunised versus control
groups when we measured totalL.major-specific responses, these data
further support our argument of altered cytokine milieu following
immunisation with a single peptide in the context of an influenza viral
vector. As the total antileishmanial responses were assessed by
exposure to SLA in a 3-day in vitro culture, which allows the
amplification of total L.major specific responses as well as any LACK-
specific responses at equal rates, the expansion of L. major-specific
responses directed at multiple peptides derived from multipleL.major
proteins could mask the expansion of single LACK158–173 T cell
specificity directed at a single epitope. Such equal expansion rates of
LACK-specific andLeishmania-specific T cells may have not occurred
in vivo in immunised versus control mice.
Discussion
The development of a safe, effective and affordable antileish-
manial vaccine is a critical global public-health priority. No
vaccine is currently available and those tested so far have been
disappointing in field studies. Thus, alternative priming strategies
employing new vectors, delivery systems and adjuvants are
urgently needed. Early experimental studies established a
dichotomy between Th1-mediated protection and Th2-mediated
disease severity. Failure to mount an efficient anti-Leishmania Th1
response was shown to cause progressive disease and absence of
lesion resolution [28]. However, the Th1/Th2 paradigm has been
questioned in recent times since there is accumulating evidence
that an early IL-4 response might not be required to promote
susceptibility and there are more complexities in the mechanisms
responsible for acquired Leishmania immunity [29]. Nevertheless, it
is generally accepted that an optimal antileishmanial vaccine
should, and would trigger a Th1-type response.
Immunisation with LACK has emerged as controversial issue.
LACK appears to promote the expansion of IL-4 secreting T cells
thus skewing the response towards deleterious Th2 responses
[30,31]. Susceptible BALB/c mice that were made tolerant to
LACK had diminished early Th2 responses and were able to
develop protective Th1 responses leading to the control of L. major
infection [32]. Despite its propensity to induce Th2 type immune
responses, immunisation with recombinant LACK and IL-12
triggered short term protective responses, but failed to elicit long-
term immunity [33]. The prime/boost immunisation with vaccinia
virus expressing LACK led to protective immune responses and
partial protection in homologous [34] and heterologous [35]
challenge systems. So far, the protective efficacy of LACK has
been mainly demonstrated in the L. major model. Surprisingly,
despite its conservation amongst the Leishmania species, LACK
failed to protect against visceral leishmaniasis, although immuni-
sation induced strong Th1 responses [36]. More recently, a fusion
of LACK with HIV-1 TAT transduction domain delivered in
dendritic cells has been shown to be superior to immunisation with
LACK alone and improved disease outcome.[37] It is unclear at
present what would be a good/protective antigen for use in a
human vaccine. The LACK antigen was used in our study as a
proof of principle to investigate a novel approach to vaccine
development.
It is clear that the influenza recombinant virus used in our study
triggers protective antileishmanial immunity in the most stringent
model of disease, the susceptible BALB/c mouse. In this model,
Figure 5. Boosting with serologically distinct recombinant virus increases protective potency and longevity of IFN-c response. A)
Prime-boost with delayed challenge strategy. B) Lesion scores in mice primed with PR8-LACKins and boosted with X31-LACKins (PR8/X31); and wild
type PR8/X31 virus controls. C) Parasite burdens in PR8/X31 vaccinated mice and virus controls (n = 5 each time point, except n = 4 for wk 10
controls), *p = 0.049. D) Cytokine production following challenge. Spleens and dNL from vaccinated and control mice were assessed by ex vivo ICS for
IFN-c production. Mean, pooled data 6 SEM are plotted (n = 3 for non-challenged mice, n = 5 for wk 2 and 6; *p = 0.02, **p = 0.01). Cells have been
gated on CD4+ CD44+.
doi:10.1371/journal.pone.0033161.g005
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mice do not normally heal, which does not entirely reflect L. major
infection in humans that usually self-resolve, but due to this reason
any protective effect observed in these mice is highly relevant. In
addition, not all CL patients self-heal easily, as there is a significant
fraction that develops severe disease [38,39]. The influenza vector
provides an ideal delivery for a Leishmania vaccine capable of
stimulating highly desirable Th1-type T cell responses, and is also
an excellent tool for T cell analysis at a high level of resolution. We
have demonstrated that a single-dose immunisation with a single,
immunodominant epitope induces strong Th1 responses in the
context of recombinant influenza vector. These responses provide
partial protection in vaccinated animals that is linked to IFN-c
production by epitope specific CD4+ T cells. It is interesting to
note that following priming only, we observed a discrepancy
between the disease manifestation at the site of infection (lesion
scores) and the site of parasite clearance (parasite burdens). This
lack of correlation might be partially attributed to a greater
frequency of regulatory T cells that are generated by infection and
accumulate in the dermis where they suppress the ability of the
effector T cells to eliminate parasites. This process has been linked
to the production of IL-10 [40], a cytokine that is also implicated
in the maintenance of parasite persistence [41]. This discrepancy
was not observed in our subsequent experiments, where our
boosting strategy with serologically distinct recombinant virus, led
to a further improvement in the protection against leishmaniasis
and increased longevity of IFN-c responses. Interestingly, the
number of LACK158–173-specific IFN-c producing T cells detected
after Leishmania challenge in the spleen is not increased greatly over
pre-challenge levels established after prime-boost with LACK158–
173 delivered in the context of influenza vectors. These
observations are consistent with our previous findings of the
staggering stability of secondary influenza-specific memory T cells
established after prime-boost scenario [42]. As shown in our
previous publication, secondary influenza-specific T cells are
extremely stable in the spleen and their numbers do not subside at
all until at least d 274 after the secondary boost, for at least some
epitopes. In addition, approximately 50% of those T cells on d 274
after secondary boost retain their CD62Llow effector phenotype,
thus are strategically positioned and ready to fight the recurrent
infection. Such great stability of memory T cells established after
influenza priming and boosting further confirms the beneficial use
of the influenza vector for eliciting long-term antileishmanial T cell
responses. Furthermore, as previously observed for the influenza
system [43] although T cells can expand following a second viral
exposure, interestingly, tertiary exposure to the antigen appears to
have a minimal, further effect. Thus, it is not surprising that
LACK158–173-specific CD4
+ T cell numbers are not increased
greatly after the challenge (tertiary antigen exposure). Part of the
reason for this may be that Leishmania challenge of H1N1-
LACK158–173RH3N2-LACK158–173 primed-boosted mice is sub-
stantially controlled early after infection, though it is also possible
that there may be inherent physiological maxima that ultimately
limit the size of these responses in lymphoid tissue.
Protection observed in our system is linked to the high numbers
of LACK158–173-specific IFN-c producing CD4
+ T cells induced in
the spleens. In all experiments, these levels are significantly higher
than those observed in control, non-immunised animals. More-
over, the levels of LACK158–173-specific IFN-c producing CD4
+ T
cells are markedly although not significantly higher compared to
the pre-challenged levels, which is consistent in all our experiments
(cell percentages are shown in Fig. S3). As discussed above these
cells are either stable and do not subside or the expansion of this
pool of cells was more pronounced at an earlier time point (eg.
wk 1), hence at wk 2 their post-challenge levels are not
significantly greater than pre-challenge levels. At the same time,
our prime-boost approach (Fig. 4) shows expansion of LACK158–
173-specific IFN-c producing CD4
+ T cells in dLN of immunised
mice, which at wk 6 are still expanding in dLN, although this
effect is not observed in our delayed challenge experiment (Fig. 5).
Interestingly, the levels of LACK-specific CD4+ T cells have not
expanded dramatically following boosting compared to priming
only, however, the protective efficacy of prime-boost approach was
significantly better. It remains unclear why the levels of IFN-c
producing LACK-specific cells have not increased, but it is well
established that CD4+ memory T cells, proliferating in response to
restimulation, divide for a shorter period of time and as a
consequence do not expand significantly following recall response
[44]. Importantly, there is generally enhanced avidity (i.e. quality)
of boosted T cell responses, thus the prime-boost vaccination could
have generated a higher ratio of multifunctional Th1 CD4+ T
cells, which have been shown to be more efficient effector cells
[45]. In this case, a more efficacious immune response could be
achieved without further expansion of cell numbers. Additionally,
the low-avidity CD4+ T cell responders have been shown to have
diminished survival capacity and are rapidly eliminated [46].
Therefore, the pool of primed CD4-specific T cells could have
Figure 6. Cytokine production profile of Leishmania specific T cells following long-term prime-boost immunisation. Cells were
obtained from spleens and dLN of immunised and control mice on wk 2 following challenge. Cells were cultured in vitro in the presence of SLA for
72 h, and culture supernatants were analysed for cytokine production. IFN-c (Th1) levels in splenocytes culture supernatants, and Th2-type cytokine
production in dLN on wk 2 post-infection measured by Bio-Plex Pro Mouse Cytokine assay. Mean, pooled data 6 SD are plotted (n = 5).
doi:10.1371/journal.pone.0033161.g006
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been initially reduced and then expanded following boosting to
seemingly the same magnitude, but with much better quality of
response.
In addition, the magnitude of response is controlled by the
duration of secondary stimulus [47] and it has also been observed
that CD4+ memory cells can decline in numbers in mice [48],
which in turn can lead to smaller numbers following recall. It has
also been reported that the efficacy of T cell responses correlates
with the number of memory T cells in peripheral sites rather than
in secondary lymphoid organs [49]. It is therefore possible that
there were significantly larger numbers of effector memory T cells
in the peripheral tissue, which allowed them to respond more
efficiently o Leishmania challenge. The above scenarios might be
responsible for the apparent lack of expansion of LACK-specific
CD4+ T cells following boosting.
The analysis of cytokine profile following SLA stimulation
indicates a clear trend towards elevated levels of detrimental Th2-
type cytokines in non-immunised controls, which can be linked to
the lack of protection. Our previous work [22] showed that the
most striking differences in cytokine production between immu-
nised and control animals occur at wk 1 post-challenge. It is
therefore, likely that higher levels of Th2 cytokines at an early time
point were decisive in directing the response towards non-
protective Th2 response in control animals, but not in the
immunised animals which could mount protective Th1 response
even in the apparent absence of elevated levels of Th1-type
cytokines at the early time point post-challenge.
Although protection has been observed, it needs to be
acknowledged that high-dose needle challenge has some draw-
backs when it comes to linking the correlates of protective
immunity with vaccine efficacy against natural infection. Peters
et al. [50] have demonstrated that sand fly transmission of parasites
abrogates vaccine-induced protective immunity. While mice
vaccinated with killed parasites were refractory to a needle
challenge, they were susceptible to the sand fly inoculum implying
that the responses in vaccinated mice required for protection were
either not generated or not maintained. On the other hand, mice
that healed the primary lesion were protected against sand fly
challenge, and the rapidity of the response suggested that the
protective response was not derived from the central memory, but
rather from an effector pool of T cells that could have been
maintained by the persistent parasites. Therefore, the influenza-
vectored vaccine would need to be tested in a natural model of
infection to assess its full efficacy.
The influenza virus itself skews the response towards highly
desirable Th1-type, but importantly, it also engages host pattern
recognition receptors, such as Toll receptors [51], stimulating the
innate immune system which in turn enhances the adaptive
responses triggered by the vaccine. The influenza system also
offers the prospect of inducing cytotoxic CD8+ T cells, which
contribute to the disease outcome. Initially, antileishmanial CD8+
T cells were thought to play a role only during re-infection [52],
however, they were subsequently shown to be crucial in
controlling the primary infection by skewing the responses towards
Th1 [53,54]. Beside cytokine production, CD8+ T cells are also
thought to participate in controlling the infection through
cytotoxic mechanisms, but the exact route of CD8+ T cell
activation in leishmaniasis is still not known. Since the parasites
reside in a parasitophorous vacuole inside the host macrophages it
is not entirely clear how these cells present antigen through MHC
I [55,56]. The most likely mechanism is cross-presentation, which
has been well documented for macrophages and DCs [57,58], but
to date has not been demonstrated in Leishmania infection. We
analysed the CD8+ contribution in the spleen and dLN at wk 2
and 6 post-challenge, following 3 day in vitro stimulation with SLA.
Although, the differences did not reach the level of statistical
significance (Fig. S1), our data show that at wk 2 in the spleen of
immunised mice there were higher numbers of antigen experi-
enced IFN-c+ CD4+ and CD8+ T cells compared to controls. In
particular, the contribution of CD8+ T cells was substantially
greater to that of CD4+ T cells, which is consistent with their
reported role in the rapid resolution of secondary infection in re-
challenged and vaccinated mice [59]. However, as the vaccine
does not trigger LACK-specific CD8+ T cells, those cells would
not be elicited after either a prime or boost with influenza-LACK
vaccine. Thus, we expect that CD8+ T cell responses observed in
our experiment are broadly Leishmania-specific as they respond to
SLA stimulation. Therefore, the delivery of leishmanial epitopes in
the context of influenza vector can facilitate the class I
presentation in addition to class II presentation of a recombinant
peptide. The capacity to readily manipulate the immunogenic
peptide in the context of influenza vector makes it easy to adapt
the vaccine for a number of candidate antigens. As the vector can
be manipulated by reverse genetics to include multiple epitopes,
this approach has the capacity to generate broad protective
responses with the potential to overcome HLA restriction and
provide immunological coverage to the broader host population.
Regions of up to 240 aa have been successfully cloned into the NA
region and viruses rescued [7], thus providing scope for insertion
of polytopic fragments. Alternatively, combinations of recombi-
nant vectors expressing single epitopes could be used to increase
the efficacy of the vaccine.
A potential obstacle for a vaccine based on a viral vector is
safety. However, there is already a precedent in using live,
temperature sensitive influenza virus in a FluMist vaccine
approved by the FDA (live-attenuated, intranasal vaccine) [60].
Moreover, the insertion of foreign sequences into the NA segment
results in a virus that can express the recombinant peptide as part
of the NA protein, but cannot release virus progeny from infected
cells [61]. In our study, insertion of the 16 aa LACK158-173 peptide
into the viral NA led to a decrease in viral replication on d 3 after
intranasal inoculation (Fig. S2) and mild symptoms of influenza
infection (modest weight loss) when compared to mice infected
with WT PR8 virus (50 pfu) which showed severe signs of infection
(loss of body weight, ruffled fur, unresponsiveness). Furthermore, a
reversion to the replication-competent NA-deficient virus via
recombination with a WT virus is highly unlikely.
Vaccination with a virally-vectored vaccine triggers an immune
response against the recombinant antigen as well as the vector.
Although a homologous boost approach is feasible, it usually leads
to diminished responses and affects the immunogenicity of a
vaccine as in a case of vaccinia-based vaccines [62]. Due to annual
changes (antigenic drift) within the NA and HA segments,
antibody protection is specific to a particular strain of influenza.
Thus, antibody-based anti-influenza vaccines need to be updated
annually. Hence, it is highly unlikely that there will be pre-existing
humoral immunity to the particular viral strain used as a vaccine
vector. Furthermore, the vector can be manipulated by reverse
genetics to avoid any possible neutralising humoral immunity and
thus allow periodical boosting. Our data indicate that boosting
with serologically different recombinant influenza increased the
immunogenicity of the vaccine, resulted in significantly better host
protection and increased the longevity of the IFN-c-driven
immune response.
An additional advantage of using influenza-vectored vaccines is
that they can be used as effective vaccines against seasonal
influenza viruses. Recent study using recombinant influenza
expressing West Nile Virus domain III of glycoprotein E [63],
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demonstrated that in addition to inducing protective levels of
antibodies and CD4+ T cells directed against the West Nile Virus,
vaccination also induced humoral responses against the vector at
protective levels. Therefore, the influenza vector system might be a
suitable platform for development of bivalent vaccine against
leishmaniasis and influenza.
Vaccination is by far the most cost effective means of control for
infectious diseases such as leishmaniasis and the recombinant
influenza viruses might provide an attractive alternative vector for
its delivery. Although LACK might not be the eventual vaccine
molecule, the successful generation of recombinant influenza
viruses expressing Leishmania-specific epitopes and the demonstra-
tion that protection can be induced in the most susceptible animal
model of disease, provide proof of concept that an influenza-
vectored vaccine is feasible and worthy of future development/
investigation.
Supporting Information
Figure S1 CD8+ T cells contribution to antileishmanial
immunity following prime-boost immunization regi-
men. Cells were obtained from spleens of immunised and control
mice on wk 2 following challenge. Cells were cultured in vitro in the
presence of SLA for 72 h, and restimulated with PMA and
ionomycin in the presence of brefeldin A for 4 h at 37oC, followed
by in vitro ICS for IFN-c production.
(TIF)
Figure S2 Viral replication kinetics following intranasal
infection with the WT PR8 and recombinant PR8-LACK
viruses. Naı¨ve mice were infected with either WT PR8 or the
mutant PR8-LACKins virus. Lungs were sampled at days 3 and 9
after infection and homogenized for titration in a standard plaque
assay. The results are log10 pfu per lung. Individual mouse
(symbols) and a mean value (line) are shown. *p,0.05.
(TIF)
Figure S3 Percentages of LACK+ IFN-c producing CD4+
T cells. A) Primed only mice; B) Short-term primed-boosted
mice; C) Long-term primed-boosted mice. Mean, pooled data 6
SEM are plotted (n numbers as per legends to Fig. 3, 4 and 5,
respectively).
(TIF)
Table S1 Amino acid sequences of the regions flanking
LACK158-173 within the influenza neuraminidase of the H1N1
A/PR8/34 (PR8) and the H3N2 A/HKx31 (X31) virus (LACK aa
sequence underlined).
(DOC)
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